- Zacks Small Cap Research•5 days ago
On October 19, 2016, AbbVie (ABBV) announced in cooperation with Neurocrine Biosciences, Inc. (NBIX) the presentation of results from two pivotal Phase 3 clinical trials evaluating the efficacy and safety of elagolix in premenopausal women who suffer from endometriosis at the 72nd American Society for Reproductive Medicine Scientific Conference & Expo (ASRM). The data show that patients treated with elagolix had a statistically significant reduction in scores for both menstrual pain (dysmenorrhea, DYS) and non-menstrual pelvic pain (NMPP).
- PR Newswire•7 days agoAbbVie Announces Positive Pivotal Phase 3 Data Demonstrating Investigational Medicine Elagolix Reduces Menstrual and Non-Menstrual Pelvic Pain Associated with Endometriosis at the American Society for Reproductive Medicine Scientific Congress
NORTH CHICAGO, Ill., Oct. 19, 2016 /PRNewswire/ -- AbbVie (ABBV), a global biopharmaceutical company in cooperation with Neurocrine Biosciences, Inc. (NBIX), today announced detailed results from two replicate pivotal Phase 3 clinical trials evaluating the efficacy and safety of Elagolix in premenopausal women who suffer from endometriosis. The data demonstrate that, compared to placebo at month three and month six, patients treated with Elagolix reported statistically significant reductions in scores for menstrual pain (dysmenorrhea, DYS) and non-menstrual pelvic pain (NMPP) associated with endometriosis as measured by the Daily Assessment of Endometriosis Pain scale.
- Insider Monkey•14 days ago
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) just notified markets that the FDA has accepted a new drug application (NDA) for its lead drug candidate, Ingrezza, and alongside the acceptance, has set a PDUFA target action date of April 11, 2017 for the drug. It’s up for priority review, shortening the wait until PDUFA, and chances of approval […]
Neurocrine Biosciences Inc. (NBIX)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
|Bid||32.00 x 100|
|Day's Range||44.27 - 46.01|
|52wk Range||31.25 - 58.46|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-32.18|
|Avg Vol (3m)||770,223|
|Dividend & Yield||0.00 (0.00%)|